ketoconazole has been researched along with ceftazidime in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bizzarri, B; Carradori, S; D'Ascenzio, M; De Monte, C; Grande, R; Mari, E; Patsilinakos, A; Ragno, R; Rivanera, D; Sabatino, M; Secci, D; Zicari, A | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Fu, L; Gao, Z; Jiang, F; Jiang, X; Liu, W; Zhang, W; Zhuang, H | 1 |
| Fu, L; Jiang, F; Jiang, X; Liu, W; Zhang, W; Zhuang, H | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Akdemir, A; Bizzarri, B; Bolasco, A; Caprara, F; Carradori, S; De Monte, C; Mari, E; Mollica, A; Rivanera, D; Secci, D; Zicari, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Aktumsek, A; Bizzarri, B; Carradori, S; Chimenti, P; De Monte, C; Mari, E; Mollica, A; Rivanera, D; Secci, D; Zengin, G; Zicari, A | 1 |
| Fu, L; Jiang, F; Jiang, X; Liu, J; Liu, W; Macho, JM; Xie, D; Zhang, W | 1 |
1 review(s) available for ketoconazole and ceftazidime
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for ketoconazole and ceftazidime
| Article | Year |
|---|---|
Synthesis, biological evaluation and quantitative structure-active relationships of 1,3-thiazolidin-4-one derivatives. A promising chemical scaffold endowed with high antifungal potency and low cytotoxicity.
Topics: Antifungal Agents; Candida; Carbon-13 Magnetic Resonance Spectroscopy; Drug Screening Assays, Antitumor; Gram-Negative Bacteria; Gram-Positive Bacteria; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Proton Magnetic Resonance Spectroscopy; Quantitative Structure-Activity Relationship; Thiazolidines | 2017 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Synthesis and antimicrobial evaluation of new benzofuran derivatives.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacillus subtilis; Bacterial Infections; Benzofurans; Candida albicans; Candidiasis; Cell Proliferation; Escherichia coli; Humans; Hydrophobic and Hydrophilic Interactions; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus; Structure-Activity Relationship | 2011 |
Design, synthesis and antimicrobial activity of chiral 2-(substituted-hydroxyl)-3-(benzo[d]oxazol-5-yl)propanoic acid derivatives.
Topics: Anti-Infective Agents; Candida albicans; Drug Design; Gram-Negative Bacteria; Gram-Positive Bacteria; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Propionates; Spectrometry, Mass, Electrospray Ionization; Stereoisomerism | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Anti-Candida activity and cytotoxicity of a large library of new N-substituted-1,3-thiazolidin-4-one derivatives.
Topics: 14-alpha Demethylase Inhibitors; Anti-Bacterial Agents; Antifungal Agents; Candida; Chemistry Techniques, Synthetic; Drug Design; Drug Evaluation, Preclinical; Fungal Proteins; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Small Molecule Libraries; Sterol 14-Demethylase; Structure-Activity Relationship; Thiazolidines | 2016 |
Novel 1,3-thiazolidin-4-one derivatives as promising anti-Candida agents endowed with anti-oxidant and chelating properties.
Topics: Antifungal Agents; Antioxidants; Candida; Chelating Agents; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Thiazolidines; Toxicity Tests | 2016 |
Design, synthesis and antimicrobial evaluation of novel benzoxazole derivatives.
Topics: Anti-Infective Agents; Bacillus subtilis; Benzoxazoles; Candida albicans; Chemistry Techniques, Synthetic; Drug Design; Microbial Sensitivity Tests | 2017 |